Capricor Therapeutics, Inc. is a clinical-stage biotechnology company focused on the discovery, development, and commercialization of first-in-class cell and exosome-based therapeutics for the treatment and prevention of diseases. The company's lead product candidate, CAP-1002, is a cell-based therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy and COVID-19. Capricor Therapeutics, Inc. was founded in 2005 and is headquartered in Beverly Hills, California.